التفاصيل البيبلوغرافية
| العنوان: |
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. |
| المؤلفون: |
Iurlo, Alessandra, Palandri, Francesca, Maria Elli, Elena, Cattaneo, Daniele, Bucelli, Cristina, Sciumè, Mariarita, Vincelli, Donatella, Brioschi, Filippo, Auteri, Giuseppe, Croci, Giorgio Alberto, Guerneri, Silvana, Isimbaldi, Giuseppe, Sabattini, Elena, Cortinovis, Ivan, Bossi, Anna, Rosti, Vittorio, Martino, Bruno, Baldini, Luca, Gianelli, Umberto |
| المصدر: |
Hematological Oncology; Feb2021, Vol. 39 Issue 1, p123-128, 6p |
| مصطلحات موضوعية: |
DIAGNOSIS, MYELOFIBROSIS, ACTINIC keratosis, BONE marrow, LACTATE dehydrogenase, KARYOTYPES, DEATH certificates |
| مستخلص: |
We analyzed cytogenetic data at diagnosis in 395 primary myelofibrosis (PMF) patients to evaluate any possible association between karyotype and WHO 2017 classification and its impact on prognosis. All the cases were diagnosed and followed at five Italian Hematological Centers between November 1983 and December 2016. An abnormal karyotype (AK) was found in 69 patients and clustered differently according to bone marrow fibrosis grade as it was found in 31 (27.0%) cases with overt fibrotic and 38 (13.6%) with pre‐fibrotic PMF (p = 0.001). Sex, anemia, thrombocytopenia, circulating blasts ≥1%, higher lactate dehydrogenase, and International Prognostic Scoring System risk classes were all significantly associated with karyotype. At a median follow‐up of >6 years, 101 deaths were recorded. Survival was different between AK and normal karyotype (NK) patients with an estimated median overall survival (OS) of 11.6 and 25.7 years, respectively (p = 0.0148). In conclusion, in our cohort around 20% of patients had an AK, more frequently in subjects with an advanced bone marrow fibrosis grade and clinical‐laboratory features indicative of a more aggressive disease. This study shows that an AK confers a more severe clinical phenotype and impacts adversely on OS, thus representing an additional parameter to be considered in the evaluation of PMF prognosis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
